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Abstract
Purpose Autologous Matrix-Induced Chondrogenesis
(AMIC®) utilizing a type I/III collagen membrane was com-
pared with microfracture (MFx) alone in focal cartilage le-
sions of the knee at one, two and five years.
Methods Forty-seven patients (aged 37±10 years, mean de-
fect size 3.6±1.6 cm2) were randomized and treated either
with MFx, with sutured or glued AMIC® in a prospective
multicentre clinical trial.
Results After improvement for the first two years in all sub-
groups, a progressive and significant score degradation was
observed in the MFx group, while all functional parameters
remained stable for least five years in the AMIC® groups. At
two and five years, MRI defect filling was more complete in
the AMIC® groups. No treatment-related adverse events were
reported.
Conclusions AMIC® is an effective cartilage repair procedure
in the knee resulting in stable clinical results significantly
better than the MFx group at five years.
Keywords Articular cartilage . AutologousMatrix-Induced
Chondrogenesis (AMIC®) . Chondro-Gide® . Knee surgery .
Microfracture
Introduction
Cartilage has a low intrinsic regenerative and reparative capac-
ity, and cartilage defects can potentially lead to severe osteoar-
thritis in the long term. Avariety of surgical techniques that aim
to resurface and repair the damaged articular cartilage include
perforation of the subchondral bone, mosaicplasty, and autolo-
gous chondrocyte transplantation. Marrow stimulation
methods, such as microfracturing (MFx), involve penetration
of the subchondral bone plate to access the bone marrow com-
partment. The resulting blood clot enriched with bone marrow
elements is thought to provide a favourable microenvironment
for the development of the cartilage repair tissue. This so-called
superclot is capable of further stimulating the migration, prolif-
eration, and chondrogenic differentiation of mesenchymal stem
cells from the bone marrow [1]. Currently, microfracturing as
well as mosaicplasty is recommended as the treatment of choice
for smaller cartilage defects (<2 cm2) [2], while autologous
chondrocyte implantation (ACI) can be an alternative therapeu-
tic option for larger defects [3, 4]. Reasons to improve the
microfracture procedure were given by various recent reviews
and studies showing unfavourable long term results, especially
in larger lesions [4, 5]. In a meta-analysis, microfracture effec-
tively improved knee function in all studies during the first 18-
24 months after microfracture, but the reports on durability
were conflicting [6].
In Autologous Matrix-induced Chondrogenesis (AMIC®),
the microfracturing is directly followed by the application of
the biodegradable natural collagen type I/III membrane
Chondro-Gide® (Geistlich Pharma AG, Wolhusen,
Switzerland) to host and hold the superclot generated by
microfracturing [7]. The principle of the AMIC® technique
was proven in a sheep model [8]. So far, promising clinical
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results with the AMIC technique were reported by case series
only [9, 10].
In order to investigate the mid-term clinical benefit of
AMIC®, a prospective, randomized controlled clinical trial
(RCT) was designed to compare AMIC® to classical
microfracture in knee cartilage lesions >2 cm2, with a follow-
up of five years. We hypothesize that adding a collagen mem-
brane, fixed either by gluing or sutering, to the conventional
microfraturing like in any AMIC® procedure would result in
better clinical and morphological results in these patients.
Material and methods
Study design
A prospective, randomized, controlled trial (RCT) was de-
signed to assess the efficacy and safety of the AMIC® tech-
nique compared to MFx alone in the treatment of small-to-
medium size cartilage defects of the knee.
Patients between 18 and 50 years of age with one or two
isolated cartilage defects of the knee grade III or IVaccording
to the Outerbridge classification [11], located either on the
medial or lateral femoral condyle, trochlea or patella and a
defect size between 2 and 10 cm2 were enrolled in the study.
Patients with more than two defects, two corresponding de-
fects or bilateral defects were excluded, as were those with
signs of osteoarthritis, bone lesions deeper than 0.7 cm, axis
deviation of more than±5° in the frontal plane and unresolved
knee instability. Further exclusion criteria were: rheumatoid
arthritis, infectious diseases, endocrine, metabolic or autoim-
mune diseases, previous subtotal or total meniscus resection
or mosaicplasty, treatment with cartilage specific medication
(e.g., hyaluronic acid), and chondropathia patellae, patella
dysplasia or patella instability. Thus, any patient with concom-
itant lesions of anterior cruciate ligament, meniscus or axial
malalignement was excluded from enrolment in the study.
Microfracture (MFx) was applied in every patient as the
basic therapy. Patients were randomly assigned to one of three
study groups receiving the following treatments:
microfracture alone (MFx), sutured AMIC® or glued
AMIC® by drawing a sealed envelope. The study endpoints
included clinical evaluation as well as MRI evaluation at one,
two and five years follow-up. All patients provided informed
written consent before arthroscopy and also agreed to comply
with a strict post-operative physiotherapy program.
According to a power analysis, the study was originally
planned to include 120 patients, 40 in each group.
Accordingly, computer assisted block randomization was car-
ried out in blocks of 30, explaining the variability of the pa-
tients recruited in each group. Because of the study design
comparing a total arthroscopic procedure (MFx alone) with
an open procedure (AMIC® glued or AMIC® sutured) neither
the patient nor the physicians were blinded.
The study was approved by the Ethics Committee (03-088
and 03/173-MZ, ZKS, University of Regensburg) and was
conducted according to the declaration of Helsinki and Good
Clinical Practice.
Sixty-seven patients were initially enrolled (18 MFx, 27
AMIC® glued and 22 AMIC® sutured) in seven centres in
Germany. Five centres with a low recruitment number (<6
patients) were closed after the collection of the two years fol-
low-up. The analysis presented here includes 47 patients en-
rolled in two centers which reached the study endpoint at
five years follow-up.
Surgical procedures
MFx was performed according to the technique published by
Steadman et al. [12] as an arthroscopic procedure. For the
AMIC® groups, a miniarthrotomy and microfracturing was
performed, and a collagen type I/III membrane (Chondro-
Gide®, Geistlich Pharma AG, Wolhusen, Switzerland) was
added to cover the microfractured defect area. Chondro-
Gide® was placed with the porous layer facing the bone sur-
face and fixed either using sutures (PDS 5.0, Ethicon,
Norderstedt, Germany; sutured AMIC®) or by gluing the ma-
trix with fibrin glue (Tissucol, Baxter, Unterschleissheim,
Germany; glued AMIC®) (Fig. 1).
Post-operative rehabilitation program
The staged rehabilitation program was standardized for all treat-
ment groups. In brief, it included foot sole contact for six weeks
using crutches building up full weight bearing after eight weeks.
Range of motion was restricted to 0/0/30° in defects of the
patella or trochlea and 0/0/60° of the femoral condyle for the
first ten days post-operatively and to 0/0/90° for six weeks for
both groups. Mobilization exercises including continuous pas-
sive motion, electrotherapy of leg muscles and proprioception
training were provided. Jogging was allowed after six months
and contact sports were restricted for 18 months [13].
Assessment of clinical outcome and safety
Clinical outcome was assessed by using the Modified
Cincinnati [14] and Modified ICRS [15] scores and a visual
analogue scale for the subjective functional status of the knee
from 0 (no pain) to 100 (severe pain). Functional status was
rated from normal to severely abnormal according to the ICRS
Cartilage Injury Standard Evaluation Form-2000 [15]. The
function of the knee was evaluated by the surgeon utilizing
parts three, four and seven of the ICRS form. Safety was
evaluated by physical examination and monitoring of adverse
events.
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MRI analysis
Structural repair was assessed with magnetic resonance imaging
(MRI, 1.5 T) by an independent and blinded radiologist, with a
focus on the extent, signal intensity, and surface of the defect
filling, integration to adjacent cartilage, and bone marrow lesion
(BML). The adapted scoring system used takes into account a
variety of features that are currently believed to be relevant to the
integrity of cartilage repair tissue as used in the MOCART-score
[16] after ACI and semiquantitative MRI-scores of osteoarthritis
established as BLOKS [17] and WORMS [18].
Histological analysis of biopsies at two years
The repair tissue was assessed by perpendicular osteochondral
biopsy material from patients who have consented to the proce-
dure, analyzed centrally by an independent and blinded patholo-
gist. The evaluationwas carried out according to the International
Cartilage Repair Society (ICRS) histology score [19].
Statistical analysis
Inferential data analysis of treatment effects was performed by
the Brunner-Langer-approach [20], suitable for analyzing de-
signs of this type with the significance level of 5% is used as a
threshold for hypotheses testing. For each of the endpoints
listed in the next section, two questions were addressed:
1. Do the values differ systematically over time? (e.g., main
effect of time)
2. Do the changes over time differ systematically between treat-
ments? (e.g., interaction effect between treatment and time)
All statistical analyses were performed using the statistics
software R version 3.0.3 [21].
Results
Baseline characteristics
Forty-seven patients were randomized and treated (13 MFx,
17 AMIC® glued, 17 AMIC® sutured) (Fig. 2). Mean patient
age at surgery was 37 years (range 21-50) and the mean defect
size after debridement was 3.6 cm2 (range 2.1-6.6 cm2).
Lesions were mostly located on the femoral condyles and
about 50% of patients had previous surgeries on the affected
knee. Baseline characteristics were largely comparable be-
tween groups (Table 1).
Clinical outcomes
MeanModified Cincinnati score (Fig. 3) increased significant-
ly from baseline values of 38±19 for the MFx group, 48±15
for the glued AMIC® group and 45 ± 19 for the sutured
AMIC® group to 72±18 (p<0.001), 67±26 (p=0.028) and
82±15 (p<0.001), respectively, at one year post-operation.
At two years, 37 patients could be evaluated. The scores
still increased in the MFx and AMIC® glued groups, to 74
±26 and 85±18, respectively, whereas a slight non-significant
decrease versus 1 year values was noted in the sutured
AMIC® group. The mean change from baseline to two years
post-operation was comparable.
After five years, 39 patients could be evaluated. The
Modified Cincinnati score was at least stable or even
Fig. 1 Images of the AMIC®
surgical technique (right medial
femoral condyle): micofracture of
the debrided defect (a);
subchondral bleeding after
microfracture (b); imprint and
trimming Chondo-Gide®
membrane (c); Chondro-Gide®
membrane is sutured into the
defect with the porous layer
facing the bone surface (d)
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improving in both AMIC® treated groups, whereas a signifi-
cant decrease was observed in the MFx group (p = 0.002
AMIC® glued, p=0.01 AMIC® sutured).
The Modified ICRS score for pain (Figs. 4 and 5) showed a
significant decrease of pain for all groups. Baseline pain was 57
±22, 46±20, and 54±19 for patients assigned to the MFx, the
glued AMIC® and the sutured AMIC® groups, respectively. At
one year post-operation pain decreased significantly to 15±17
for MFx (p<0.001), 15±13 (p<0.001) for glued AMIC® and
16±15 (p<0.001) for sutured AMIC®. After five years, both
AMIC® treated patient groups still reported very low pain,
whereas pain increased non-significantly in the MFx group.
Functional scoring
Almost all patients rated their status as abnormal before surgery
(92.3% in the MFx group, 100% in the AMIC® glued and 100%
in theAMIC® sutured groups, respectively). This rating improved
for all patient groups at one year, where only 11-23% of patients
had an abnormal or severely abnormal status at two years. At
five years, 66% of the patients in the MFx group were again in
the abnormal ranking range and none of these patients were con-
sidered to have a normal knee, whereas in the AMIC groups,
severe ranking was only reported by 6-7% of the patients.
Similarly, the objective functional status was abnormal or
severely abnormal pre-operatively for about 80% of the pa-
tients in each group. After one year, functional improvement
was noted in all groups, lowering the group of severely affect-
ed patients to 25-35% after one year. After two years, the
proportion of abnormal or severely abnormal status was noted
in 33% of patients in the MFx group and 0-7% in the AMIC®
treated groups. After five years, the abnormal/severely abnor-
mal patient populations amounted to 66% in the MFx group
and 0-7% in the AMIC® groups. Finally, 90-100% of the
AMIC® treated patients had improved to a normal or nearly
normal functional status, whichever assessment was made.
MRI evaluation
At one year post operation, 35-50% of the patients had a defect
filling of two thirds or more. Complete integration could be
observed in 15-30% of patients in the different groups.
Allocation
Follow-up
Enrollment 47 patients (2 centers)
13 patients randomized to
microfracture
17 patients randomized to
AMIC® glued
17 patients randomized to 
AMIC® sutured
11 patients available at 1 year
Drop out: n=1 (ACI)
Lost to follow-up: n=1
Not available: n=0
9 patients available at 2 years
Drop out: n=0
Lost to follow-up: n=1 (revision)
Not available: n=1
9 patients available at 5 years
Drop out: n=0
Lost to follow-up: n=1
15 patients available at 1 year 
Drop out: n=1 (TKA)
Lost to follow-up: n=0
Not available: n=1
15 patients available at 2 years
Drop out: n=0
Lost to follow-up: n=1
Not available: n=0
14 patients available at 5 years
Drop out: n=0
Lost to follow-up: n=1
13 patients available at 1 year 
Drop out: n=0 
Lost to follow-up: n=0
Not available: n=4
13 patients available at 2 years 
Drop out: n=0
Lost to follow-up: n=0
Not available: n=4
16 patients available at 5 years  
Drop out: n=0
Lost to follow-up: n=1 
Fig. 2 Baseline demographics and stratification of the ITT population of the two centers continuing follow-up for five years
Table 1 Overview of the patient
demographics and baseline
characteristics (two centers)
Total MFx AMIC® glued AMIC® sutured
Patients (n) 47 13 17 17
Ø Age (±SD) 37 ± 10 40± 6 39± 9 34± 11
Ø Weight (kg ± SD) 84 ± 12 80± 10 87± 10 84± 15
Ø BMI (±SD) 26.8 ± 3.9 25.0 ± 2.9 27.6 ± 4.0 27.4 ± 4.4
Sex (m/f) 37 m/10f 10 m/3f 15 m/2f 12 m/5f
Previous operation (yes) 24 6 8 10
Ø Defect size after debridement (±SD) 3.6 ± 1.6 2.9 ± 0.8 3.9 ± 1.1* 3.8 ± 2.1
Meniscus revision (yes) 15 6 4 5
* significance versus MFx: p = 0.01
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At two years, the defect filling was more complete in the
AMIC® treated groups, where at least 60% of the patients had
a defect filling of more than two-thirds. In the MFx group,
only 25% of the patients achieved such filling.
At five years post operation, the defect filling was the lowest
in theMFx group, versus both AMIC® treated groups (Table 2).
Histological evaluation
Biopsies were obtained at two years only in two patients, both
belonging to the AMIC sutured group. Both showed the pres-
ence of a fibrocartilaginous matrix, without evidence of resid-
ual membrane material, and in one case cell cluster formation
was observed in the deep zone of the repair tissue. Hyaline
cartilage specific markers were identified, as Safranin-O,
collagen-type I and II and a glycosaminoglycan. Both repair
tissue were characterized as mostly fibrocartilagenous.
Safety
One patient treated with glued AMIC® received a joint replace-
ment after one year and one patient with MFx received an ACI
procedure after one year. For the complete study population, 13
adverse events were reported in nine patients. No serious ad-
verse event related to the treatment was reported for any patient.
Discussion
AMIC® combines MFx treatment with a collagen membrane
(Chondro-Gide®) andwas developed to treat small- to medium-
sized cartilage defects (>2 cm2). The hypothesis funding this
RCTwith AMIC® in focal cartilage defects of the knee was that
the use of a coveringmembrane in an AMIC® procedure would
result in sustained benefit compared to microfracturing alone at
Fig. 3 Modified Cincinnati
score. Number of patients
available at five years follow-up
(n): Microfracture (9), AMIC
glued (14, p = 0.002), and AMIC
sutured (16, p = 0.01); *
significance versus Microfracture
at five years
Fig. 4 Modified ICRS score–
pain. Number of patients
available at five years follow-up
(n): Microfracture (8), AMIC
glued (13), and AMIC sutured
(16)
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five years. This was confirmed by our results. After improve-
ment for the first two years in all subgroups, a progressive and
significant score degradation was observed in the MFx group,
while all functional parameters remained stable for at least
five years in the AMIC® groups. Both modes of Chondro-
Gide® fixation resulted in similar mid-term clinical benefit. At
two years and later, defect filling in MRI was notably more
complete in the AMIC® treated groups (at least 60% of the
patients had a defect filling of more than 2/3) compared to the
MFx group with only 25% of such a filling. At five years the
defect filling was the lowest in the MFx group.
Overall, our data are in agreement with the results of Gille
et al. reporting a significant improvement in clinical outcomes
in patients treated with AMIC®, assessed by five different
scores up to 36 months [22]. Similar results were found in a
larger multicentre observational study including 57 patients
Table 2 MRI evaluation



















Defect filling none 0 0 1 1 1 2 2 3 4
1/3 3 2 4 0 3 2 1 2 1
1/3-2/3 3 2 2 5 1 3 5 1 1
>2/3 5 2 2 9 10 4 6 8 6
not evaluable 0 0 0 1 0 0 0 0 0
Surface largely uneven 4 3 5 2 2 4 4 3 3
partially uneven 4 1 3 11 6 3 6 4 4
smooth 3 3 0 2 6 2 2 4 1
not evaluable 0 0 1 1 1 2 2 3 4
Integration marginal gap up to
50%
1 2 4 0 1 4 2 1 0
marginal gap 8 1 4 10 9 3 5 3 2
complete 1 4 0 5 4 2 4 6 5
not evaluable 1 0 1 1 1 2 3 4 5
Signal intensity of
defect cover
inhomogeneous 8 3 7 7 5 7 7 5 7
homogenous 3 4 1 8 9 2 5 6 1
not evaluable 0 0 1 1 1 2 2 3 4
Bone marrow
lesion
massive (>2 cm) 0 1 3 1 1 4 0 1 4
intermediate
(1-2 cm)
5 1 3 4 6 3 4 6 4
small (<1 cm) 5 3 2 7 6 3 9 7 4
none 0 2 1 4 2 1 1 0 0
not evaluable 1 0 0 0 0 0 0 0 0
Fig. 5 Example of MRI (1.5 T) follow-up at one, two and five years
(glued AMIC®, medial femoral condyle): Proton density weighted
sequence (PDw) in sagittal orientation with defect filling almost
complete (20 × 20 mm, see arrow), surface remaining slightly uneven,
good marginal integration, and repair tissue nearly isointense to
adjacent genuine cartilage
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with grade III or IV chondral lesions evaluated two-years
post-operatively [23]. Pascarella et al. evaluated the results
of AMIC® using Pridie perforations instead of MFx, assessed
up to 36 months with significant improvement in clinical
scores and reduction of the defect area [24]. Similar results
were shown for 17 patients with a larger mean defect size and
76% of the patients were satisfied or extremely satisfied [25].
Kusano et al. evaluated outcomes of 38 patients treated with
AMIC® for full-thickness chondral and osteochondral defects
of the femoral condyles and patella [26]. After a mean follow-
up of 29 months, significant improvements in clinical out-
come scores were noted where the largest improvements were
seen in the osteochondral subgroup.
Discussion and justification of the study design is neces-
sary for several reasons. When AMIC® was developed,
Chondro-Gide® was thought to be sutured to the defect site,
as in ACI. However, since fixation with fibrin glue had been
established for MACI, a third group—glued AMIC®—was
added. Meanwhile, gluing is routinely carried out and has
proven to be a feasible fixation technique. No different failure
rate associated with the fixation mode of the membrane was
seen in our study favoring the use of glue for fixation. In 2003,
when the study was designed, contemporary classification and
outcome scores for cartilage were used. Here the Outerbridge
classification for defect grading and Modified Cincinnati, not
specific for cartilage repair and the Modified ICRS score was
chosen.
The inclusion/exclusion criteria for this study were very
restrictive. It was extremely difficult to convince patients to
participate, since they did not want to be treated randomized.
Hence, recruitment was very slow and therefore centers with
low activity had to be closed after their patients reached the
two year follow-up. Though requested, not all patients did
show for every controls as scheduled for personal reasons
explaining the varying numbers at different follow-ups. The
rather small resulting sample size of each group might there-
fore hide some of the nonsignificant differences observed in
this study. Moreover, since patients did not agree to undergo
biopsy as a routine, only two biopsies could be analyzed at
two years. Therefore, the exclusive morphological cartilage
repair assessment became based on MRI. In this study, MRI
defect filling was more complete in the AMIC® groups at two
and five years. In this context, two recent meta-analyses of de
Windt et al. [27] and of Blackman et al. [28] pointed out that
conclusive evidence to determine whether morphological
MRI is reliable in predicting clinical outcome after cartilage
repair is lacking. These reports also stated that no MRI clas-
sification has been shown to correlate with clinical outcomes
after different types of cartilage repair. This was supported by
the study of Shive et al., comparing in an RCT the BST-
CarGel treatment with microfracture [29]. The authors were
able to show a significantly better defect filling in the treated
group versus MFx, whereas no clinical or functional
difference could be established between the groups. Since
the interpretation of cartilage structure from morphological
MRI data is still debated and does not correlate with clinical
outcomes, the clinical and functional scores were considered
as the primary outcomes here.
Conflicting data have also been published regarding the
durability of different cartilage repair strategies. Although
some groups have reported mid- and long-term survival rates
of approximately 75% after MFx [30], others have observed
that good short-term results are not maintained in the long-
term [5]. This was the case in the recently reported RCT,
comparing MFx to MFx associated to BST-CarGel [29].
These authors did not find a difference in the clinical scoring
and no impairment of the WOMAC score was detected be-
tween one and five years. They suggested that when per-
formed properly, MFx can effectively improve pain and func-
tion despite the widely reported clinical outcome expectancy
of two to three years. However, in this RCT, the mean lesion
area was of 2.08 to 2.4 cm2 in the MFx or MFx+BST-CarGel
groups respectively. This small lesion size may explain the
five years of stable results observed in the MFx group.
To the best of our knowledge, to date, no randomized con-
trolled studies have been published comparing AMIC® with
other cartilage repair procedures. Data from our RCT confirm
the general consensus of a progressive decrease of the
microfracture benefit after two years. This finding is reflected
in the literature, particularly when the lesion size was larger
than 2 cm2 [6, 31, 32]. Our mean lesion size was 3.6±1.6 cm2
representing mid-sized lesions and our findings in the MFx
group can clearly prove progressive degradation after
two years. No treatment-related adverse events were reported.
Conversely, we can confirm that all clinical variables
remained stable at least five years following surgery indepen-
dent of which AMIC® procedure was used. Both modes of
Chondro-Gide® fixation resulted in similar short-term and
mid-term beneficial clinical outcomes.
As a conclusion, AMIC® is an effective cartilage repair
procedure in the knee resulting in stable clinical results signif-
icantly better than the MFx group at five years.
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